Research Article
Fibroblast Activation Protein Expression in Sarcomas
Table 4
Active clinical trials investigating therapeutics targeting FAP for which patients with sarcoma may be eligible.
| Intervention | Intervention type | Study population | Phase | NCT number |
| 177-Lu-FAP-2286 | Peptide-targeted radionuclide therapy | Adults with refractory/progressive advanced/metastatic solid tumors | Phase 1/2 | NCT04939610 | MP0317 | Designed ankyrin repeat protein (DARPin®) drug targeting FAP and CD40 | Adults with relapsed/refractory advanced solid tumors | Phase 1 | NCT05098405 | RO7300490 as a single agent or combined with atezolizumab | RO7300490 is a bispecific antibody | Adults with advanced solid tumors | Phase 1 | NCT04857138 | RO6874281 as a single agent or combined with trastuzumab or cetuximab | RO6874281 is a bispecific targeted IL-2 variant with the antibody component targeted against FAP | Adults with advanced/metastatic solid tumors | Phase 1 | NCT02627274 | Nectin4/FAP targeted fourth-generation CAR-T cells | CAR-T | Adults with advanced malignant solid tumors | Phase 1 | NCT03932565 |
|
|
Abbreviation key: FAP = fibroblast activation protein; CAR-T: chimeric antigen receptor (CAR)-T cell therapies.
|